Management of Radiation-Induced Cerebral Necrosis

Radiation-induced cerebral necrosis is a serious late complication of cranial radiotherapy, characterised by progressive brain tissue damage arising months to years after exposure. Endothelial cell loss and blood–brain barrier breakdown provoke chronic hypoxia, inflammation and reactive gliosis, culminating in focal necrosis and vasogenic oedema. Clinical manifestations range from cognitive impairment to focal neurological deficits, challenging long-term survivors of primary brain tumours and metastatic disease. Diagnostic accuracy has improved through advanced neuroimaging modalities—including perfusion MRI, magnetic resonance spectroscopy and amino acid PET—which aid differentiation from tumour recurrence. Management strategies aim to stabilise the blood–brain barrier, reduce oedema and restore neurological function. Corticosteroids remain first-line but carry systemic side effects. Targeted anti-VEGF agents have emerged as effective steroid-sparing options, while hyperbaric oxygen, surgical resection and novel neuroprotective approaches are under investigation. Individualised care pathways integrate risk factors such as prior chemotherapy and irradiated volume to optimise outcomes.

Research from Nature Portfolio

Recent studies have advanced understanding of targeted vascular modulation and imaging biomarkers in radiation necrosis. A foundational report in Scientific Reports described a cohort of patients treated with bevacizumab following stereotactic radiotherapy. Bevacizumab administered at 5 mg/kg every three weeks led to significant reductions in necrosis volume and perilesional oedema on MRI, accompanied by marked clinical improvement. The safety profile was favourable, supporting further evaluation of optimised dosing schedules. This work emphasises the therapeutic potential of VEGF inhibition in mitigating late-stage radiation injury and informs the design of prospective trials exploring personalised anti-angiogenic regimens.

Management of Radiation-Induced Cerebral Necrosis publication trend

The graph below shows the total number of articles in management of radiation-induced cerebral necrosis across all publications each year (not limited to Nature Index journals).

Technical terms

Radiation-induced cerebral necrosis: Focal brain tissue death resulting from delayed radiation injury to vasculature and glial cells.

Stereotactic radiosurgery (SRS): Precise delivery of high-dose radiation to target lesions with minimal exposure to surrounding tissue.

Bevacizumab: A monoclonal antibody against vascular endothelial growth factor (VEGF) used to reduce pathological angiogenesis and oedema.

Vascular endothelial growth factor (VEGF): A protein that promotes blood vessel formation and increases vascular permeability.

Magnetic resonance spectroscopy (MRS): A non-invasive imaging technique that analyses tissue metabolite concentrations to distinguish necrosis from tumour recurrence.

References

1. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Scientific Reports (2016).
2. Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis. Frontiers in Immunology (2024).
3. Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series. Cancers (2023).